NFI Announces Election of Directors
WINNIPEG, Manitoba, May 12, 2025 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI) a leader in propulsion-agnostic bus and coach mobility solutions, is pleased to announce that the ten nominees listed in the
management information circular
dated March 21, 2025, were elected as directors of the Board at the Company's annual and special meeting of shareholders (the Shareholder Meeting) held on Friday May 9, 2025. The detailed results of the vote for the election of directors held at the Shareholder Meeting are set out below.
Final voting results on all matters voted on at the Shareholder Meeting will be available at
www.nfigroup.com
and will be filed with the Canadian securities regulators and available on SEDAR at
www.sedarplus.ca
.
About NFI
Leveraging 450 years of combined experience, NFI offers a wide range of propulsion-agnostic bus and coach platforms, including market leading electric models. Through its low- and zero-emission buses and coaches, infrastructure, and technology, NFI meets today's urban demands for scalable smart mobility solutions. Together, NFI is enabling more livable cities through connected, clean, and sustainable transportation.
With nearly 9,000 team members in ten countries, NFI is a leading global bus manufacturer of mass mobility solutions under the brands New Flyer® (heavy-duty transit buses), MCI® (motorcoaches), Alexander Dennis Limited (single- and double-deck buses), Plaxton (motorcoaches), ARBOC® (low-floor cutaway and medium-duty buses), and NFI Parts™. NFI currently offers the widest range of sustainable drive systems available, including zero-emission electric (trolley, battery, and fuel cell), natural gas, electric hybrid, and clean diesel. In total, NFI supports its installed base of over 100,000 buses and coaches around the world. NFI's common shares trade on the Toronto Stock Exchange (TSX) under the symbol NFI and its convertible unsecured debentures trade on the TSX under the symbol NFI.DB. News and information is available at
www.nfigroup.com
,
www.newflyer.com
,
www.mcicoach.com
,
nfi.parts
,
www.alexander-dennis.com
,
arbocsv.com
, and
carfaircomposites.com
.
For investor and media inquiries, please contact:
Stephen King
P: 204.792.1300
Stephen.King@nfigroup.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Tesla officially launches robotaxis in Austin to a small group of users, charging a $4.20 flat fee per ride
On a balmy Sunday in Austin, Tesla fans awaited the promise of the future. After a few hours of delays, that promise finally came true, and a select group took their first rides, livestreaming their experience. While Tesla robotaxis are meant to be fully autonomous, Tesla employees were still present in the passenger seat of the cars for safety reasons. Earlier this month, Tesla CEO Elon Musk teased the launch of the robotaxi, a driverless Tesla Model Y emblazoned with its namesake in Cybertruck-style font. "Beautifully simple design," Musk wrote on X. "These are unmodified Tesla cars coming straight from the factory, meaning that every Tesla coming out of our factories is capable of unsupervised self-driving," he added. On Sunday, Musk said the first Tesla robotaxi rides would be available for a flat fee of $4.20. A small group of invited users was the first to try them out. Tesla fans buzzed on social media in the lead-up to the official launch, which was initially delayed as users awaited the release of the official Tesla robotaxi app. "We are approaching the window where we expected to have the app and showing everything," Chuck Cook, one of the early invitees to try the Tesla robotaxi, said on X. "There looks like there will be a small delay in the distribution of the app for couple hours." Tesla AI, the division behind the robotaxis, said Sunday on X that Tesla robotaxis will eventually be deployed anywhere they are approved and are designed for "scalability." "It does not require expensive, specialized equipment or extensive mapping of service areas. It just works," the company said. The company launched a website where users can sign up for early access when the service becomes available in their area. It also launched an X feed dedicated to Tesla robotaxis. With the launch of Tesla robotaxis, Austin continued to solidify itself as a new theater for Silicon Valley's race to shape the new age of driverless transportation. In March, Google-backed Waymo launched its autonomous ride-hailing service in partnership with Uber. Waabi, a Canadian startup backed by Uber and Nvidia, is set to launch fully autonomous trucks in Texas this year. Zoox, backed by Amazon, opened its first robotaxi serial production facility in Austin last week. This is a developing story. Check back for updates.
Business Upturn
4 hours ago
- Business Upturn
OGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting Investors have until July 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Hauser v. Organon & Co., et al. , No. 25-cv-05322. Why was Organon Sued for Securities Fraud? Organon is a global healthcare company focused on women's health that has historically rewarded its shareholders with a healthy dividend. In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company focused on dermatological conditions. As alleged, while the acquisition increased Organon's debt, the Company assured investors it would maintain its dividend, which Organon asserted was its '#1 capital allocation priority.' In truth, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt, ultimately leading the Company to severely cut its dividend. The Stock Declines as the Truth is Revealed On May 1, 2025, Organon announced that management reset the Company's dividend payout from $0.28 per share to $0.02 per share. Organon's CEO explained that the Company 'reset our capital allocation priorities to accelerate progress towards deleveraging' and that '[b]y deleveraging more rapidly, we will continue to strengthen the future prospects of the company.' Organon's CFO added, '[t]he biggest issues we face . . . relate to managing our leverage and relate to growth. And we need capital to solve both of those issues, and so returning capital to shareholders is right now, less of a priority.' On this news, the price of Organon stock declined roughly 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025. Click here if you suffered losses: What Can You Do? If you invested in Organon you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
4 hours ago
- Business Upturn
IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al. , No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company's authorized treatment centers ('ATCs'). As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance's ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs. The Stock Declines as the Truth is Revealed On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was 'revising full-year 2025 revenue guidance.' The Company blamed 'recent launch dynamics,' including slow 'treatment timelines for new ATCs' and 'the variable pace at which ATCs began treating patients,' which 'differs from center to center.' Iovance also blamed the poor results on high 'patient drop-off' due to inadequate 'patient selection' for treatment. On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025. Click here if you suffered losses: What Can You Do? If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
